POST Online Media Lite Edition


Akers Biosciences seals U.S. distribution agreement for heparin test

Staff Writer |
Health information technology company Akers Biosciences has entered a three-year hospital distribution agreement covering the United States.

Article continues below

The national distribution agreement will see Diagnostica Stago market and sell Akers' PIFA PLUSS PF4 product, a test for heparin sensitivity, across its broad existing customer base of hospital laboratories.

John Gormally, chief executive of Akers Bio, said: "Through Stago, Akers Bio will gain access to a dedicated and specialized sales team who are focused exclusively on buyers of hemostasis-related products. Akers Bio is excited about the potential for near-term US sales growth through this new, additional and specialized channel to market."

The PIFA PLUSS PF4 is designed to rapidly determine, in under one hour, whether a patient being treated with widely used blood thinner heparin may be developing a reaction known heparin-induced thrombocytopenia, which can risk the limbs and life of patients.

According to Akers, there are approximately 4m tests for HIT conducted annually in the US using slower traditional methods which the company hopes to replace with its rapid alternative.

Phillippe Barroux, North America chief executive of Stago, said: "Stago is pleased to have selected PIFA PLUSS PF4 rapid assay as its only rapid test for heparin Platelet Factor 4 antibodies in the U.S.

"Our sales team is looking forward to communicating the compelling medical and economic benefits of this uniquely efficient and accurate test for heparin-induced thrombocytopenia to Stago's customers in line with our commitment to providing market leading hemostasis solutions to improve patient care."

What to read next

Daiichi Sankyo to Acquire Ambit Biosciences
SKF signs agreements with Scania worth SEK 360 million
Hercules Fluid Power Group to invest $1m, employ 50 in Florida